Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | CA6 | P23280 | 1/20 | 0.44 |
| ▸ | CA5A | P35218 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.44 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1425647 | 0.98 | HPGD (0.43) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| SCHEMBL24140260 | 0.84 | HPGD (0.47) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| Hydrochloric Acid SCHEMBL10494767 | 0.81 | HPGD (0.42) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| SCHEMBL1275070 | 0.81 | HPGD (0.42) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| Hydrochloric Acid SCHEMBL2869306 | 0.80 | HPGD (0.41) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| SCHEMBL10494811 | 0.80 | ALDH1A1 (0.44) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| SCHEMBL631823 | 0.80 | CYP3A4 (0.46) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| SCHEMBL9528190 | 0.80 | CA1 (0.47) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| SCHEMBL955244 | 0.80 | PSIP1 (0.48) | HPGDLMNAHTTSMN1; SMN2CA1 | |
| SCHEMBL2077991 | 0.79 | CA1 (0.50) | HPGDLMNAHTTSMN1; SMN2CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10736878-B2 | Treatment of organophosphate exposure with triptans | PFADENHAUER TINA (US) | 2020-08-11 | — | — | US | disclosed |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | RESPIVERT LTD. (GB) | 2018-07-19 | — | — | US | disclosed |
| EP-2582700-B1 | RESPIRATORY FORMULATIONS CONTAINING P38 MAPK INHIBITORS | RESPIVERT LTD (GB) | 2016-11-02 | — | — | EP | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-9024041-B2 | P38 MAP kinase inhibitors | RESPIVERT LTD. (GB) | 2015-05-05 | — | — | US | disclosed |
| US-8933228-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2015-01-13 | — | — | US | disclosed |
| US-8933228-B2 | Respiratory formulations and compounds for use therein | Respivert, Ltd. (GB) | 2015-01-13 | — | — | US | disclosed |
| US-20140024641-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TRIPTANS | HELTON DAVID REED (US) | 2014-01-23 | — | — | US | disclosed |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | RESPIVERT LIMITED (GB) | 2013-06-20 | — | — | US | disclosed |
| EP-1009738-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 2000-06-21 | — | — | EP | disclosed |
| EP-0462837-B1 | Preparation of indole derivatives | GLAXO GROUP LTD (GB) | 2000-04-05 | — | — | EP | disclosed |
| WO-1999015500-A1 | SUBSTITUTED OXINDOLE DERIVATIVES AS PROTEIN TYROSINE KINASE AND AS PROTEIN SERINE/THREONINE KINASE INHIBITORS | GLAXO GROUP LIMITED (GB) | 1999-04-01 | — | — | WO | disclosed |
| EP-0793661-A1 | PIPERAZINE, PIPERIDINE & TETRAHYDROPYRIDINE DERIVATIVES USEFUL AS 5-HT1 RECEPTOR AGONISTS | MERCK SHARP & DOHME LTD. (GB) | 1997-09-10 | — | — | EP | disclosed |
| WO-1996016056-A1 | PIPERAZINE, PIPERIDINE & TETRAHYDROPYRIDINE DERIVATIVES USEFUL AS 5-HT1 RECEPTOR AGONISTS | MERCK SHARP & DOHME LIMITED (GB) | 1996-05-30 | — | — | WO | disclosed |
| US-5103020-A | Reacting 4-hydrazino-n-methylbenzenemethanesulfonamide and 4-chloro-1-hydroxybutanesulphonic acid, sodium salt in presence of acid | GLAXO GROUP LIMITED (GB) | 1992-04-07 | — | — | US | disclosed |
| US-5103020-A | Reacting 4-hydrazino-n-methylbenzenemethanesulfonamide and 4-chloro-1-hydroxybutanesulphonic acid, sodium salt in presence of acid | GLAXO GROUP LIMITED (GB) | 1992-04-07 | — | — | US | disclosed |
| EP-0462837-A2 | Preparation of indole derivatives | GLAXO GROUP LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
| EP-0462837-A2 | Preparation of indole derivatives | GLAXO GROUP LIMITED (GB) | 1991-12-27 | — | — | EP | disclosed |
| US-4816470-A | Heterocyclic compounds | GLAXO GROUP LIMITED | 1989-03-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140024641-A1 | TREATMENT OF ORGANOPHOSPHATE EXPOSURE WITH TRIPTANS | DDT, THOP1, TPP1 | HPGD 1263/4885LMNA 2107/4885HTT 1248/4885 |
| US-20130156826-A1 | RESPIRATORY FORMULATIONS AND COMPOUNDS FOR USE THEREIN | TSLP, CCL11, RORB | HPGD 222/4885LMNA 2963/4885HTT 4326/4885 |
| US-10736878-B2 | Treatment of organophosphate exposure with triptans | DDT, THOP1, TPP1 | HPGD 1263/4885LMNA 2107/4885HTT 1248/4885 |
| US-20180201611-A1 | Respiratory formulations and compounds for use therein | TSLP, CCL11, RORB | HPGD 222/4885LMNA 2963/4885HTT 4326/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.